ADC’s Phase II Data May Position ‘Lonca’ To Compete With Roche’s Polivy

 
• By Joseph Haas
Lymphoma cancer cell - 3d rendering
ADC Therapeutics thinks Lonca has broad potential across lymphoma settings

More from Clinical Trials

More from R&D